Hepatitis delta virus inhibits alpha interferon signaling

Paolo Pugnale, Valerio Pazienza, Kévin Guilloux, Francesco Negro

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Hepatitis delta virus (HDV) can cause severe acute and chronic liver disease in patients infected with hepatitis B virus. Interferon-α (IFN-α) is the only treatment reported to be effective in chronic hepatitis delta, albeit in a minority of patients. The molecular mechanisms underlying resistance to therapy are unclear. IFN-α-induced activation of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling cascade is essential for the induction of an antiviral state. Interference of HDV with the JAK-STAT pathway could be responsible for the IFN-α resistance in chronic hepatitis delta patients. We analyzed IFN-α-induced signal transduction through the JAK-STAT pathway in human hepatoma cells transfected with the complete HDV genome. The expression of IFN-α-stimulated genes was investigated with reverse transcription real-time polymerase chain reaction (PCR). STATs and JAKs activations were examined by immunofluorescence and immunoblot. The IFN-α-stimulated genes coding for the antiviral proteins myxovirus resistance A, double-stranded RNA (dsRNA)-activated protein kinase and 2′,5′-oligoadenylate synthetase were down-regulated in HDV-transfected hepatoma cells in response to IFN-α treatment. HDV severely impaired the phosphorylation of both STAT1 and STAT2, thus preventing their accumulation in the nucleus. Furthermore, HDV blocked the IFN-α-stimulated tyrosine phosphorylation of IFN receptor-associated JAK kinase Tyk2, without affecting either the tyrosine phosphorylation of Jak1 or the expression of type I IFN receptor subunits. Conclusions: IFN-α-induced intracellular signaling is impaired in HDV-transfected human hepatoma cells. HDV subverts the effect of IFN-α by blocking Tyk2 activation, thereby resulting in selective impairment of activation and translocation to the nucleus of STAT1 and STAT2. Interference of HDV with IFN-α signaling could represent an important mechanism of viral persistence and treatment resistance.

Original languageEnglish
Pages (from-to)398-406
Number of pages9
JournalHepatology
Volume49
Issue number2
DOIs
Publication statusPublished - 2009

Fingerprint

Hepatitis Delta Virus
Interferon-alpha
Interferons
Janus Kinases
Chronic Hepatitis D
Transducers
Hepatocellular Carcinoma
Phosphorylation
Antiviral Agents
Tyrosine
Myxovirus Resistance Proteins
eIF-2 Kinase
Double-Stranded RNA
Therapeutics
Ligases
Hepatitis B virus
Genes
Reverse Transcription
Fluorescent Antibody Technique
Liver Diseases

ASJC Scopus subject areas

  • Medicine(all)
  • Hepatology

Cite this

Hepatitis delta virus inhibits alpha interferon signaling. / Pugnale, Paolo; Pazienza, Valerio; Guilloux, Kévin; Negro, Francesco.

In: Hepatology, Vol. 49, No. 2, 2009, p. 398-406.

Research output: Contribution to journalArticle

Pugnale, P, Pazienza, V, Guilloux, K & Negro, F 2009, 'Hepatitis delta virus inhibits alpha interferon signaling', Hepatology, vol. 49, no. 2, pp. 398-406. https://doi.org/10.1002/hep.22654
Pugnale, Paolo ; Pazienza, Valerio ; Guilloux, Kévin ; Negro, Francesco. / Hepatitis delta virus inhibits alpha interferon signaling. In: Hepatology. 2009 ; Vol. 49, No. 2. pp. 398-406.
@article{bf726b4428ec4d81a0d6750e5421ea57,
title = "Hepatitis delta virus inhibits alpha interferon signaling",
abstract = "Hepatitis delta virus (HDV) can cause severe acute and chronic liver disease in patients infected with hepatitis B virus. Interferon-α (IFN-α) is the only treatment reported to be effective in chronic hepatitis delta, albeit in a minority of patients. The molecular mechanisms underlying resistance to therapy are unclear. IFN-α-induced activation of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling cascade is essential for the induction of an antiviral state. Interference of HDV with the JAK-STAT pathway could be responsible for the IFN-α resistance in chronic hepatitis delta patients. We analyzed IFN-α-induced signal transduction through the JAK-STAT pathway in human hepatoma cells transfected with the complete HDV genome. The expression of IFN-α-stimulated genes was investigated with reverse transcription real-time polymerase chain reaction (PCR). STATs and JAKs activations were examined by immunofluorescence and immunoblot. The IFN-α-stimulated genes coding for the antiviral proteins myxovirus resistance A, double-stranded RNA (dsRNA)-activated protein kinase and 2′,5′-oligoadenylate synthetase were down-regulated in HDV-transfected hepatoma cells in response to IFN-α treatment. HDV severely impaired the phosphorylation of both STAT1 and STAT2, thus preventing their accumulation in the nucleus. Furthermore, HDV blocked the IFN-α-stimulated tyrosine phosphorylation of IFN receptor-associated JAK kinase Tyk2, without affecting either the tyrosine phosphorylation of Jak1 or the expression of type I IFN receptor subunits. Conclusions: IFN-α-induced intracellular signaling is impaired in HDV-transfected human hepatoma cells. HDV subverts the effect of IFN-α by blocking Tyk2 activation, thereby resulting in selective impairment of activation and translocation to the nucleus of STAT1 and STAT2. Interference of HDV with IFN-α signaling could represent an important mechanism of viral persistence and treatment resistance.",
author = "Paolo Pugnale and Valerio Pazienza and K{\'e}vin Guilloux and Francesco Negro",
year = "2009",
doi = "10.1002/hep.22654",
language = "English",
volume = "49",
pages = "398--406",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Hepatitis delta virus inhibits alpha interferon signaling

AU - Pugnale, Paolo

AU - Pazienza, Valerio

AU - Guilloux, Kévin

AU - Negro, Francesco

PY - 2009

Y1 - 2009

N2 - Hepatitis delta virus (HDV) can cause severe acute and chronic liver disease in patients infected with hepatitis B virus. Interferon-α (IFN-α) is the only treatment reported to be effective in chronic hepatitis delta, albeit in a minority of patients. The molecular mechanisms underlying resistance to therapy are unclear. IFN-α-induced activation of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling cascade is essential for the induction of an antiviral state. Interference of HDV with the JAK-STAT pathway could be responsible for the IFN-α resistance in chronic hepatitis delta patients. We analyzed IFN-α-induced signal transduction through the JAK-STAT pathway in human hepatoma cells transfected with the complete HDV genome. The expression of IFN-α-stimulated genes was investigated with reverse transcription real-time polymerase chain reaction (PCR). STATs and JAKs activations were examined by immunofluorescence and immunoblot. The IFN-α-stimulated genes coding for the antiviral proteins myxovirus resistance A, double-stranded RNA (dsRNA)-activated protein kinase and 2′,5′-oligoadenylate synthetase were down-regulated in HDV-transfected hepatoma cells in response to IFN-α treatment. HDV severely impaired the phosphorylation of both STAT1 and STAT2, thus preventing their accumulation in the nucleus. Furthermore, HDV blocked the IFN-α-stimulated tyrosine phosphorylation of IFN receptor-associated JAK kinase Tyk2, without affecting either the tyrosine phosphorylation of Jak1 or the expression of type I IFN receptor subunits. Conclusions: IFN-α-induced intracellular signaling is impaired in HDV-transfected human hepatoma cells. HDV subverts the effect of IFN-α by blocking Tyk2 activation, thereby resulting in selective impairment of activation and translocation to the nucleus of STAT1 and STAT2. Interference of HDV with IFN-α signaling could represent an important mechanism of viral persistence and treatment resistance.

AB - Hepatitis delta virus (HDV) can cause severe acute and chronic liver disease in patients infected with hepatitis B virus. Interferon-α (IFN-α) is the only treatment reported to be effective in chronic hepatitis delta, albeit in a minority of patients. The molecular mechanisms underlying resistance to therapy are unclear. IFN-α-induced activation of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling cascade is essential for the induction of an antiviral state. Interference of HDV with the JAK-STAT pathway could be responsible for the IFN-α resistance in chronic hepatitis delta patients. We analyzed IFN-α-induced signal transduction through the JAK-STAT pathway in human hepatoma cells transfected with the complete HDV genome. The expression of IFN-α-stimulated genes was investigated with reverse transcription real-time polymerase chain reaction (PCR). STATs and JAKs activations were examined by immunofluorescence and immunoblot. The IFN-α-stimulated genes coding for the antiviral proteins myxovirus resistance A, double-stranded RNA (dsRNA)-activated protein kinase and 2′,5′-oligoadenylate synthetase were down-regulated in HDV-transfected hepatoma cells in response to IFN-α treatment. HDV severely impaired the phosphorylation of both STAT1 and STAT2, thus preventing their accumulation in the nucleus. Furthermore, HDV blocked the IFN-α-stimulated tyrosine phosphorylation of IFN receptor-associated JAK kinase Tyk2, without affecting either the tyrosine phosphorylation of Jak1 or the expression of type I IFN receptor subunits. Conclusions: IFN-α-induced intracellular signaling is impaired in HDV-transfected human hepatoma cells. HDV subverts the effect of IFN-α by blocking Tyk2 activation, thereby resulting in selective impairment of activation and translocation to the nucleus of STAT1 and STAT2. Interference of HDV with IFN-α signaling could represent an important mechanism of viral persistence and treatment resistance.

UR - http://www.scopus.com/inward/record.url?scp=61949094906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61949094906&partnerID=8YFLogxK

U2 - 10.1002/hep.22654

DO - 10.1002/hep.22654

M3 - Article

C2 - 19085955

AN - SCOPUS:61949094906

VL - 49

SP - 398

EP - 406

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 2

ER -